ENDRA Life Sciences (NDRA) Common Equity (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Common Equity for 11 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 1.94% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 1.94% YoY), while the FY2025 annual figure was $2.3 million, down 11.73% from the prior year.
• Common Equity slipped to $1.8 million in Q1 2026 per NDRA's latest filing, from $2.3 million in the prior quarter.
• Across five years, Common Equity topped out at $13.3 million in Q2 2022 and bottomed at $171380.0 in Q3 2025.
• Historically, Common Equity has averaged $5.4 million across 5 years, with a median of $5.2 million in 2023.
• Annual changes were most pronounced in 2024 — Common Equity advanced 29.77% — and 2025, when it plunged 97.41%.
• ENDRA Life Sciences' Common Equity stood at $7.2 million in 2022, then decreased by 21.45% to $5.7 million in 2023, then plunged by 54.76% to $2.6 million in 2024, then decreased by 11.73% to $2.3 million in 2025, then fell by 20.94% to $1.8 million in 2026.
• Business Quant data shows NDRA's Common Equity at $1.8 million in Q1 2026, $2.3 million in Q4 2025, and $171380.0 in Q3 2025.